EMPEROR-Preserved: A promise fulfilled.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34731652.
- Also identified by DOI 10.1016/j.cmet.2021.10.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest unmet needs in medicine. In the EMPEROR-Preserved trial, recently reported in the NEJM, the SGLT2 inhibitor empagliflozin reduced the primary outcome of heart failure hospitalizations and cardiovascular death by 21% in patients with HFpEF. This represents an important breakthrough in the war against heart failure.
Medical subject headings
- Heart Failure
- Sodium-Glucose Transporter 2 Inhibitors